Tris Pharma Reports the P-III (ALLEVIATE-1) Study Results of Cebranopadol to Treat Moderate-to-Severe Acute Pain
Shots:
- The P-III (ALLEVIATE-1) study assessed analgesic efficacy of cebranopadol (400µg, QD) vs PBO for treating moderate-to-severe acute pain post abdominoplasty surgery
- Study depicted significantly reduced pain intensity as evaluated by Pain Numeric Rating Scale (NRS) AUC4-48 (1.34 mean hourly difference) and a well-tolerated safety with nausea being the common AE
- Tris will present full results of ALLEVIATE-1 at future conferences and share findings from 2 additional studies: an intranasal abuse potential study & ALLEVIATE-2 (P-III bunionectomy trial) in Q1’25, with an NDA submission planned later. Chronic pain studies for cebranopadol are set to begin in H2’25
Ref: Tris Pharma | Image: Tris Pharma
Related News:- Tris Pharma Initiates Pivotal P-III Study to Evaluate Cebranopadol for Moderate-to-Severe Acute Pain
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
